Immunotherapy Combinations for Lung Cancers: Challenges and Opportunities of Rapidly Evolving Treatments

Few oncology treatment paradigms are evolving as rapidly as those for lung cancer. In particular emerging data and indications for immunotherapy combinations in both NSCLC and SCLC have resulted in an explosion of new therapeutic options. Review the program Webcast and download the slidesets to deepen your understanding of current and evolving best practices!  This is not an official program of the American Association for Cancer Research Annual Meeting.

Share

Program Content

Activities

Immunotherapy and SCLC
Immunotherapy and Small-Cell Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 01, 2019

Expires: March 30, 2020

NSCLC Combo Immunotherapy
Immune Checkpoint Inhibitor Combinations as First-line Therapy for Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 01, 2019

Expires: March 30, 2020

Future of ICIs in Lung Cancer
The Future of Immunotherapy in Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 01, 2019

Expires: March 30, 2020

Activities

IO Combos for Lung Cancer
Immunotherapy Combinations for Lung Cancers: Challenges and Opportunities of Rapidly Evolving Treatments
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2019

Expires: June 24, 2020

Faculty

cover img faculity

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

cover img faculity

Hossein Borghaei, MS, DO

Associate Professor
Chief,
Thoracic Medical Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

cover img faculity

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only